

To: Office of Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

From: Mylan Pharmaceuticals Inc.
781 Chestnut Ridge Road
Morgantown, West Virginia 26505

Date: July 24, 2020

Re: 18 V.S.A § 4637

In compliance with 18 V.S.A. § 4637, Mylan Pharmaceuticals Inc. hereby provides written notice that on July 21, 2020 it introduced the following new prescription generic drug to market:

- Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release Tablets, 10mg/10mg, 100s (the “Product”)

**Please note that, although not all courses of treatment of the Product trigger the threshold established by the Centers for Medicare and Medicaid Services for specialty drugs in the Medicare Part D program (the “threshold”), this notice is being submitted because the Product triggers the threshold only when taking into account the maximum recommended dose as listed in the Product Prescribing Information.*